AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04156828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT04156828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT04156828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT01236560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT03755479 — intervention group
Intervention type: DEVICE
Intervention: Hybrid Closed Loop Insulin Pump Minimed 670G
Description: Five Day Group Education on Minimed 670G
Study NCT01969292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colometer
Description: Real time software based image analysis tool.
Study NCT01969292 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Software
Description: Software that displays constant positive feedback that is unrelated to the quality measures of the actual colonoscopy.
Study NCT02024373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 20 mg (every evening orally) for 8 weeks
Study NCT02024373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 20 mg (every evening orally) for 8 weeks
Study NCT04156828 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT04156828 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC
Study NCT01236560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study NCT03207841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LC/HP
Description: Intervention group will receive 8 weeks of LC/HP diet. The daily LC-HP dietary intervention will include \~30% total energy as protein (1.6 g/kg per day) with a carbohydrate-to-protein ratio \<1.5 and fat intake set at \~30% of the total energy intake.
Study NCT00853086 — intervention group
Intervention type: DRUG
Intervention: activated recombinant human factor VII
Description: Safety data collection in connection with the use of the drug NovoSeven® in daily clinical practice
Study NCT00503178 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biological imaging guided antalgic radiotherapy
Description: Biological imaging guided antalgic radiotherapy is followed.
Study NCT04578106 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination
Description: After 13 weeks of neoadjuvant treatment, a breast MRI will be performed. If a complete response is observed on breast MRI, patients will undergo a stereotactic-guided VAB of the marker area to obtain 12 cylinders of breast parenchyma, which is equivalent to 2 grams of tissue. If no invasive tumor cells and no in situ disease are identified in the stereotactic-guided VAB, patients will be eligible to omit loco-regional surgery.
Study NCT01673191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant
Study NCT01673191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid plus NSAID eye drop combination therapy
Study NCT01337622 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No check of gastric residuals for early enteral feeding advancement
Description: Discontinuation of gastric feeding and its advancement will be based on clinical examination of the abdomen and gastric aspirates containing blood or significant vomiting.
Study NCT02370940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High phytate intake
Study NCT02370940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low phytate intake
Study NCT00600028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide 50 - 100 mg by mouth daily
Study NCT00600028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 50-100 mg by mouth per day
Study NCT01337622 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine check of gastric residuals for early enteral feeding advancement
Description: Discontinuation of gastric feeding and its advancement will be based on current practice of clinical examination of the abdomen and checking residual before every feed. Volume and color of gastric residual will be considered according to the current guideline.
Study NCT03516240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofreeze
Description: Following a procedure that induces muscle fatigue in the lower extremity, a topical cream will be applied over the quadriceps. The cream will be either a topical analgesic (Biofreeze) or a placebo cream. Evaluation of the movement kinematics and kinetics will be evaluated for each group.
Study NCT03516240 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Following a procedure that induces muscle fatigue in the lower extremity, a topical cream will be applied over the quadriceps. The cream will be either a topical analgesic (Biofreeze) or a placebo cream. Evaluation of the movement kinematics and kinetics will be evaluated for each group. Placebo cream will be blinded to both the experimenter and study participant. It will look and smell the same and will be in the same packaging.
Study NCT01783444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus, 5 mg tablets for oral use, 10 mg (2 x 5 mg) per day (centrally supplied)
Study NCT00532935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate (+) metformin hydrochloride
Description: sitagliptin phosphate (+) metformin hydrochloride 50/500 mg tablet bid, titrating up to sitagliptin phosphate (+) metformin hydrochloride 50/1000 mg tablet for an \~32 wk treatment period
Study NCT00532935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: pioglitazone
Description: pioglitazone 30 mg tablet qd, titrating up to 45 mg qd for an \~32-wk treatment period.
Study NCT02340845 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bromelain and Comosain
Description: Treatment of solid tumors in advanced stage of lung, breast, colon, ovary, cervix, uterus, prostatic, and liver
Study NCT03285789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passing tests in dyslexics with reduced eva
Description: Visual attention span : the subject see a 5 letters strings during 200 ms and he has to report it orally whatever the order Visual search : the subject has to find a target among distractors (24 or 48) in different conditions of stimuli (conjunction feature or separable feature) and different conditions of view (full view or reduced view with the moving window paradigm) Elementary visuo spatial perception: the subject passes 6 visuo spatial tests to judge his visuo spatial abilities.~All of these tests will be made during an unique visit of 1h30.
Study NCT03285789 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passing tests in controls
Description: Visual attention span : the subject see a 5 letters strings during 200 ms and he has to report it verbally whatever the order Visual search : the subject has to find a target among distractors (24 or 48) in different conditions of stimuli (conjunction feature or separable feature) and different conditions of view (full view or reduced view with the moving window paradigm) Elementary visuo spatial perception: the subject passes 6 visuo spatial test to judge his visuo spatial abilities.~test de l'alouette : reading test during 3 minutes, we note the number of word read and the errors. We obtain lexical age.~All of these tests will be made during an unique visit of 1h30.
Study NCT03827564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intranasal Tear Neurostimulator (ITN) [TrueTear®]
Description: The ITN applies a small electrical current to the nasal cavities to gently activate the body's natural tear production system.
Study NCT03512262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abaloparatide
Description: Abaloparatide is a synthetic peptide that is a potent and selective activator of the parathyroid hormone 1 receptor signaling pathway.
Study NCT03512262 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Abaloparatide-matched placebo.
Study NCT01248325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luffa Operculate Nasal Solution 5mg/mL
Description: The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
Study NCT01248325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Solution (NaCl 0,9%)
Description: The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
Study NCT01312480 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 5A's Model
Description: The smoking cessation intervention is based on the 5A's model, which includes the following elements:~1. Ask if the patient smokes.~2. Advise every patient to quit.~3. Assess readiness to quit.~4. Assist in quitting and finding services.~5. Arrange for cessation services and follow-up.
Study NCT02034773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220 0.3mg will be administered once daily for 14 days
Study NCT02034773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220 1mg will be administered once daily for 28 days + 1 dose of tetanus toxoid vaccination and 1 dose of pneumococcal vaccination
Study NCT02034773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220 0.3mg will be administered once daily for 28 days
Study NCT02034773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220 1mg will be administered once daily for 7 days on 2 separate occasions, with a 7-day washout in between, for a total of 14 days of dosing
Study NCT02034773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered once daily for up to 28 days
Study NCT02034773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220 0.3mg will be administered every 3 days for 14 days (5 total doses)
Study NCT02034773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220 1mg (once every 7 days for 28 days)
Study NCT02034773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220 1mg will be administered as a single dose in each of 2 study periods; once as a formulated capsule and once as two reference capsules
Study NCT03114410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Re:MIX, a multi-layer comprehensive teen pregnancy prevention intervention aimed at reducing pregnancy and STIs among youth ages 13-17
Description: Re:MIX is a comprehensive in-school health curriculum and teen pregnancy prevention program for adolescents covering a broad range of topics related to sexual health and youth development, including healthy relationships, communication, gender, consent, reproductive anatomy, contraception, sexual decision making, clinics, parenthood, and life planning. Re:MIX also aims to connect students and young parent educators with community resources and service linkages. The Re:MIX curriculum teaches mixed-gender groups of students in grades 8 to 10 to delay sex and use protection if they have sex. A co-facilitation team of young parent educators delivered the information with professional health educators using non-traditional approaches, such as game-based tools, technology, and storytelling. Youth received roughly nine hours and 10 minutes of group sessions during the school day over one semester (55 minutes per week for 10 weeks).
Study NCT01618643 — intervention group
Intervention type: PROCEDURE
Intervention: Acetic acid chromoendoscopy
Description: Prospective observational pilot study.~We would examine patients with Barrett's epithelium that is either healthy or has suspected areas of neoplasia. We will apply acetic acid spray to areas of healthy Barrett's metaplasia and time how long it takes for the aceto whitening to disappear. We will repeat this in cases referred with SM invasive cancer, intramucosal cancer, suspected high grade dysplasia and possible low grade dysplasia. We will record how long it takes for the acetowhitening to disappear. We will biopsy these areas to confirm the diagnosis.~We will correlate the histology to the aceto-whitening time to see if there is a correlation between the degree of neoplasia and the aceto-whitening time after acetic acid dye spray.
Study NCT02505321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Triglyceride Tolerance Test (OTTT)
Description: Participants consume a fatty drink. An intravenous catheter is inserted into the antecubital veins in one arm for intermittent sampling over the following 4 hours. The OTTT permits simple evaluation of postchallenge triglyceride levels and is acceptable to participants.
Study NCT02505321 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal fat biopsy (optional)
Description: A sample of abdominal fat will be obtained by firstly injecting some local anaesthetic into an accessible area of the abdomen. Using a scalpel, a small incision (approx 2-3 cm) will be made to a depth of approx 15mm and two small pea-sized samples of fat will be removed. The wound will be closed with simple sutures or steristrips.
Study NCT04960098 — intervention group
Intervention type: PROCEDURE
Intervention: arthroplasty
Description: patient with hip and knee osteoarthritis underwent hip and knee arthroplasty
Study NCT00903851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidoderm
Description: Patients participated in an 8-week treatment period; patients at one site were to continue treatment for the entire 8 weeks while patients at two sites were to terminate treatment after 3 weeks. Commercially available Lidoderm® (lidocaine patch 5%) was provided to each patient with up to four patches applied topically 18 hours on, 6 hours off per day to the area of maximal peripheral neuropathic pain.
Study NCT02284412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: At a train-of-four (TOF) ratio of 0.5: administration of neostigmine 0.06 mg/kg for reversal of neuromuscular blockade.
Study NCT02284412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: At a train-of-four (TOF) ratio of 0.5: administration of sugammadex 15 mg/kg for reversal of neuromuscular blockade.
Study NCT02284412 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water for injection
Description: At a train-of-four (TOF) ratio of 0.5: administration of placebo for spontaneous recovery of neuromuscular blockade.
Study NCT03689413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 200 MG in 2 ML Injection
Description: 1 mg/kg or 2 mg/kg intravenous injection for each group (1 mg/kg group, 2 mg/kg group) after tracheal intubation
Study NCT03689413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex 200 MG in 2 ML Injection
Description: 1 mg/kg or 2 mg/kg intravenous injection for each group (1 mg/kg group, 2 mg/kg group) after tracheal intubation
Study NCT01312480 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Media Use Assessment
Description: The media use assessment (control condition) is based in part on the American Academy of Pediatrics policy statement on children and media, published in the November 2010 issue of Pediatrics. This assessment includes suggested questions on how much media per day is used and whether or not the adolescent has a television or Internet access in his/her bedroom. The adolescent will complete a one-page Media Use assessment form for this purpose, which will set the stage for relevant anticipatory guidance.
Study NCT04494048 — intervention group
Intervention type: OTHER
Intervention: Endoscopic Bariatric Therapies
Description: Participation in this study will allow for data collection through medical chart review for at least 6 standard of care visits up to 1 year after consenting to participate in this registry study. The exposure of interest is total body weight loss, safety and efficacy
Study NCT00297869 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Decision Support
Description: Electronic warnings when providers prescribe a potentially inappropriate medication or an excessively dosed medication (based on estimated creatinine clearance)
Study NCT00556023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-675,206 and gemcitabine
Description: Escalating doses of CP-675,206 will be administered by IV infusion on day 1 of each 84-day treatment cycles (doses of 6, 10 and 15 mg/kg are planned). Gemcitabine will be administered by IV infusion, at a fixed dose of 1000 mg/m2 on days 1 (prior to CP-675,206) and again on days 8, 15, 29, 36, 43, 57, 64, and 71. Repeated cycles of gemcitabine and CP-675,206 will be administered until patients develop progressive disease or unacceptable toxicity, or for a maximum of 4 cycles, whichever occurs first.
Study NCT03148626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MINDI mindfulness curriculum
Description: A seven-session mindfulness curriculum implemented over six-months during pediatric internship.
Study NCT03148626 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Usual Education
Study NCT03916809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMST
Description: Expiratory muscle strength training (EMST) is an exercise program designed to strengthen the muscles of expiration by increasing expiratory load during breathing exercises using either resistive or pressure threshold devices. The EMST150 is a commercially-available device considered non-significant risk (NSR). The EMST150 device will be used for this study.
Study NCT03916809 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: EMST
Description: Expiratory muscle strength training (EMST) is an exercise program designed to strengthen the muscles of expiration by increasing expiratory load during breathing exercises using either resistive or pressure threshold devices. The EMST150 is a commercially-available device considered non-significant risk (NSR). The EMST150 device will be used for this study.
Study NCT04504955 — intervention group
Intervention type: OTHER
Intervention: Observational Non-Interventional Registry
Description: Observational Non-Interventional Registry
Study NCT06094452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training
Description: Participants in intervention group will receive a multidomain, adaptive computerized cognitive training program (www.66nao.com) and will be required to complete at least 30 minutes of training per day (3 cycle of 5 2-min tasks), 5 days a week for 24 weeks. Multidomain coverage paradigms include working memory, calculation, processing speed, attention, executive function, and short-term and long-term memory.
Study NCT06094452 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Patients in control group will receive TAU for 24 weeks, which includes (1) regular medication management from the Memory Clinic, if applicable; (2) basic health education at each follow-up (face to face) and twice per month on the internet .
Study NCT03660241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: PF 04965842 is a janus kinase (JAK) 1 inhibitor that is currently being developed for the treatment of atopic dermatitis (AD).
Study NCT04438343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Impairment-specific and augmented intervention
Description: Balance and lower extremities strength training
Study NCT04438343 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Trunk and upper extremity training
Study NCT03722355 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional RT
Description: Radiation therapy
Study NCT03722355 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hyperfractionated RT
Description: Radiation therapy
Study NCT03722355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carmustine
Description: Chemotherapy
Study NCT03722355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Chemotherapy
Study NCT02132754 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4166
Study NCT03703336 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ROTAVIN (liquid formulation)
Description: Live attenuated human rotavirus vaccine containing ≥ 2x10\^6 plaque forming units (PFU) of strain G1P\[8\] per dose of 2 mL.
Study NCT03703336 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ROTAVIN-M1 (frozen formulation)
Description: Live attenuated human rotavirus vaccine containing ≥ 2x10\^6 PFU of strain G1P\[8\] per dose of 2 mL.
Study NCT01064336 — intervention group
Intervention type: DRUG
Intervention: Eltrombopag
Description: Eltrombopag is an orally bioavailable, small molecule thrombopoietin receptor (TPO-R) agonist for the treatment of idiopathic thrombocytopenic purpura
Study NCT02395978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDC-1421 Capsule
Description: PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
Study NCT02132754 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT02431819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: contention socks
Description: Patients wear contention socks during 15 days.